Key result
Avapritinib is linked to a reversible Brugada ECG pattern unmasked by fever.
Case Report (n=1)
No
This case introduces a previously unrecognized association between the tyrosine kinase inhibitor avapritinib and a reversible Brugada pattern unmasked during febrile illness.
Answers are grounded in this paper and cite their sources.
May prompt ECG monitoring during fever on avapritinib; leaves open true causality and clinical relevance pending prospective data.
BACKGROUND: Brugada phenocopy is a reversible Brugada pattern on an electrocardiogram (ECG) caused by identifiable clinical conditions (such as fever, electrolyte abnormalities, or drug exposure) in patients without true congenital Brugada syndrome, which is an inherited arrhythmogenic disorder often associated with SCN5A mutations. CASE SUMMARY: . Avapritinib was withheld, and Brugada ECG pattern resolved with defervescence. Genetic testing identified a heterozygous missense variant in the JPH2 gene. DISCUSSION: We report a case of type 1 Brugada ECG pattern unmasked by febrile illness after avapritinib initiation, with an incidental finding of heterozygous missense variant in the JPH2 gene. TAKE-HOME MESSAGE: This case introduces a previously unrecognized association between avapritinib and Brugada pattern and suggests avapritinib as a potential pharmacologic trigger in susceptible individuals.
No takes yet. Share an insight, caveat, or question.
Haque et al. (2026) conducted a case report in Metastatic myeloid sarcoma with febrile illness (n=1). Avapritinib was evaluated on Resolution of Brugada ECG pattern. Avapritinib, in the presence of fever, was temporally associated with a reversible Brugada ECG pattern, representing a previously unreported potential cardiac toxicity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: